Invitation & Agenda: Orexo R&D Day on March 24

Rhea-AI Summary

Orexo (OTCQX: ORXOY / STO: ORX; symbol provided: ORXOF) invites investors, analysts and media to its R&D Day on March 24, 2026 in Stockholm. Management will outline updated strategy after the US Zubsolv divestment and present R&D priorities centred on the AmorphOX drug delivery platform.

Agenda highlights include sessions on AmorphOX applications, OX640 intranasal epinephrine, OX390 intranasal rescue medication and a prerecorded expert perspective on xylazine/medetomidine/fentanyl risks. Registration available via the company's R&D Day webpage.

Key Figures

R&D Day date: March 24, 2026

1 metrics

R&D Day date March 24, 2026 Scheduled company R&D Day event in Stockholm

Market Reality Check

Price: $3.23 Vol: Volume 327 is slightly be...

normal vol

$3.23 Last Close

Volume Volume 327 is slightly below the 20-day average of 334 (relative volume 0.98). normal

Technical Price at 3.23 is trading above the 200-day MA of 1.51.

Peers on Argus

ORXOF is up 5.9% while key peers are flat to negative: ORXOY 0%, BIOYF -5.56%, P...

ORXOF is up 5.9% while key peers are flat to negative: ORXOY 0%, BIOYF -5.56%, PLNH -0.78%, BNXTF -0.06%, MEDXF -0.11%, suggesting a stock-specific move.

Market Pulse Summary

This announcement scheduled an R&D Day on March 24, 2026, where management plans to present an updat...

Analysis

This announcement scheduled an R&D Day on March 24, 2026, where management plans to present an updated strategy following the Zubsolv® divestment and highlight AmorphOX®-based programs, including OX640 and OX390. With no new clinical results or financial metrics disclosed, investors may focus on how future presentations, trial readouts, and partnership updates evolve from the themes outlined in this agenda.

Key Terms

drug delivery, biomolecules, glp-1s, epinephrine, +4 more

8 terms

drug delivery medical

"transform drug delivery of biomolecules from unstable injectables"

Drug delivery is how a medicine is packaged, moved and released inside the body so it reaches the right place at the right time and dose. Think of it like a shipping and packaging system that affects a product’s effectiveness, side effects and convenience; better delivery can make a drug work longer, be safer, or be easier to use. Investors care because delivery methods influence a therapy’s market value, regulatory approval, manufacturing costs and competitive advantage.

biomolecules medical

"drug delivery of biomolecules from unstable injectables to convenient nasal"

Biomolecules are the natural chemicals—like proteins, DNA, sugars and fats—that do the work and form the structure of living cells, similar to the ingredients and building materials in a recipe or a house. Investors watch them because many drugs, diagnostics and biotech products target, use or measure these molecules; changes in how they are discovered, manufactured or regulated can directly affect a company’s product prospects, costs, and revenue potential.

glp-1s medical

"moving beyond nasal delivery in GLP-1s and expanding into new areas"

GLP-1s are a class of prescription medicines that mimic a natural gut hormone to lower blood sugar, curb appetite and slow stomach emptying, often used for diabetes and weight management. They matter to investors because prescribing rates, pricing and insurance coverage can drive large, sustained revenue streams and reshape demand across drug makers, medical device vendors and health insurers—like a bestselling product line that shifts an entire market.

epinephrine medical

"best-in-class nasal epinephrine product improving stability, bioavailability"

Epinephrine, also known as adrenaline, is a fast-acting hormone and medication used to stimulate the heart, open airways and tighten blood vessels during life-threatening emergencies like severe allergic reactions, asthma attacks and cardiac arrest. Investors care because its clinical use and demand drive sales of drug products and delivery devices, influence regulatory approvals and supply chains, and can quickly affect revenue and stock value when shortages, new formulations or policy changes occur.

intranasal medical

"powder-based intranasal epinephrine product candidate in development"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

medical countermeasure (mcm) medical

"world's first medical countermeasure (MCM) to the rising threat"

Medical countermeasures (MCMs) are the vaccines, drugs, tests, devices and protective supplies used to prevent, detect or treat public health threats like infectious diseases or bioterror agents. Think of them as the medical toolbox governments and healthcare systems deploy in an emergency; their development, approval and stockpiling can create sudden demand, large government contracts and regulatory scrutiny, all of which matter to investors assessing a company’s revenue and risk profile.

xylazine medical

"emerging threats linked to xylazine, medetomidine, and fentanyl combinations"

Xylazine is a veterinary sedative and pain reliever used for animals that is not approved for human use; it has increasingly been detected as an adulterant in illegal street drugs, where it can deepen sedation and cause severe health problems. Investors should care because its presence drives public health responses, testing and treatment demand, regulatory scrutiny, and potential legal or policy changes—similar to a hidden ingredient in a product that suddenly forces safety recalls and new industry rules.

fentanyl medical

"emerging threats from xylazine, medetomidine, and fentanyl combinations"

Fentanyl is a very powerful synthetic opioid used medically to treat severe pain and, in illicit form, can be deadly at much smaller doses than other painkillers. Investors pay attention because its medical use, strict regulation, growing illegal market and related legal or public‑health actions can affect drugmakers, hospitals, emergency services and broader liability or demand for treatments—similar to how a single safety issue can reshape an entire industry.

AI-generated analysis. Not financial advice.

UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The event will take place at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.

During the day, CEO Nikolaj Sørensen and the management team will outline Orexo's updated strategy and R&D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The program will also feature expert perspectives from Mark A. Smith, PhD, Davidson College, NC, US, on emerging threats linked to xylazine, medetomidine, and fentanyl combinations.

The agenda is outlined below. To register for the event, please visit the R&D Day webpage:
https://www.orexo.se/rnd-day2026

 

Time am CET	Topic or activity	Presenter
9:00 – 9.30	Registration and coffee.
9:30 – 9:45	Shaping Orexo's future: Strategic priorities and value creation.	Nikolaj Sørensen,                        President and CEO.
9:45 – 10:00	AmorphOX: A unique opportunity to transform drug delivery of biomolecules from unstable injectables to convenient nasal or tablet delivery in an established scalable commercial supply chain.	Robert Rönn, SVP and Head of R&D/ Cecilia Coupland,                     SVP and Head of Operations.
10:00 – 10:15	AmorphOX: Moving beyond nasal delivery in GLP-1s and expanding into new areas with significant market needs through preclinical innovation, and strategic partnerships.	Robert Rönn, SVP and Head of R&D/ Lisa Moore, SVP, Product and Portfolio Strategy.
10:15-10:30	OX640: Aiming for the best-in-class nasal epinephrine product improving stability, bioavailability and patient convenience to address the needs of severe allergy patients.	Robert Rönn/ Lisa Moore.
10:30-10:45	Break.
10:45-11:00	OX390: Developing the world's first medical countermeasure (MCM) to the rising threat from xylazine and medetomidine in collaboration with BARDA, a center within the US Department of Health and Human Services.	Edward Kim, SVP and Chief Medical Officer.
11:00-11:15	Expert perspectives: Why counter-measures are needed for the emerging threats from xylazine, medetomidine, and fentanyl combinations.	Mark A. Smith, PhD  Davidson College, NC, US. Dr Smith will attend through a prerecorded video.
11:15-11:30	Building a viable business model through business development.	Fredrik Järrsten, EVP and CFO, Head of Business Development.
11:30-12:00	Q&A, incl closing remarks by CEO.	All presenters.
12 pm	Lunch & networking.

Notes: OX640 is a powder-based intranasal epinephrine product candidate in development for the emergency treatment of Type I allergic reactions; OX390 is a powder-based intranasal rescue medication candidate in development for adulterated overdoses. Neither product has been approved by any regulatory agency.

Minor changes may be made to the agenda ahead of the event.

For further information contact:
Lena Wange, IR and Communications Director
Tel: +46 (0)18 780 88 00, +46 73 064 16 36
Email: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm's main market and trades as ADRs on the OTCQX market in the United States.

For more information about Orexo visit, www.orexo.com. You can also follow Orexo on X, LinkedIn and YouTube.

The information was submitted for publication at 4 pm CET, on March 6, 2026.

CONTACT:

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/invitation---agenda--orexo-r-d-day-on-march-24,c4318007

View original content:https://www.prnewswire.com/news-releases/invitation--agenda-orexo-rd-day-on-march-24-302706888.html

SOURCE Orexo

FAQ

What will Orexo (ORXOF) present at its R&D Day on March 24, 2026?

Orexo will present an updated strategy and R&D priorities, focused on AmorphOX drug delivery and product candidates. According to Orexo, management and R&D leaders will explain how AmorphOX supports nasal and tablet delivery and outline OX640 and OX390 development plans.

What is AmorphOX and why does Orexo (ORXOF) emphasize it at the March 24 R&D Day?

AmorphOX is Orexo's proprietary drug-delivery technology aimed at converting unstable injectables into nasal or tablet formats. According to Orexo, the platform targets biomolecule stability and scalable commercial supply chains and is central to the company's post-divestment R&D focus.

What are OX640 and OX390 and how do they fit Orexo's pipeline (ORXOF)?

OX640 is a powder intranasal epinephrine candidate for severe allergy; OX390 is an intranasal rescue medication candidate for adulterated overdoses. According to Orexo, both are in development and neither product has been approved by any regulatory agency.

Is Orexo (ORXOF) working with BARDA on OX390 and what does that mean?

Orexo states OX390 is being developed as a medical countermeasure in collaboration with BARDA, a U.S. health agency center. According to Orexo, the collaboration targets rising threats from xylazine and medetomidine in adulterated overdoses and supports development efforts.

How can investors register to attend Orexo's R&D Day on March 24, 2026?

Investors, analysts and media can register via Orexo's dedicated R&D Day webpage. According to Orexo, the event is at the Royal Swedish Academy of Engineering Sciences in Stockholm and includes presentations, Q&A and a networking lunch.

Will experts discuss xylazine, medetomidine and fentanyl at Orexo's (ORXOF) R&D Day?

Yes, expert perspectives on threats from xylazine, medetomidine and fentanyl combinations are included in the agenda. According to Orexo, Mark A. Smith, PhD, provides a prerecorded expert segment explaining the need for countermeasures and clinical context.